News Release

Mallinckrodt to Present at Barclays Conference March 11

DUBLIN, March 4, 2015 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global specialty biopharmaceutical company, will present at the Barclays Global Healthcare Conference at the Loews Miami Hotel in Miami, Florida, on Wednesday, March 11, 2015. Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, will represent the company in a session scheduled to begin at 10:45 a.m. Eastern.

Individuals who cannot attend the meeting in person can find webcast information on Mallinckrodt's Investor Relations website or at: A replay will also be available following the meeting.

Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide and a commercial presence in roughly 65 countries. The company's fiscal 2014 revenue totaled $2.54 billion. To learn more about Mallinckrodt, visit


Rhonda Sciarra, 314-654-8618
Manager, Communications


Meredith Fischer, 314-654-3318
Senior Vice President, Communications


John Moten, 314-654-6650
Vice President, Investor Relations

Logo -


To view the original version on PR Newswire, visit:

SOURCE Mallinckrodt